Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HNRNPA0, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) is a protein involved in RNA binding and regulation of RNA metabolism. Commonly referred to as HNRNPA0 it has a molecular mass close to 34 kDa. This protein is expressed in a variety of tissues including brain liver and spleen suggesting its widespread functional relevance. HNRNPA0 plays a role in the post-transcriptional regulation of gene expression by influencing mRNA stability and splicing.
Biological function summary
HNRNPA0 modulates RNA processing and is actively involved in mRNA decay and stabilization processes. It forms complexes with other hnRNP proteins and interacts with mRNA substrates to regulate their fate within the cell. This protein contributes to gene expression regulation under stress conditions by altering the stability of specific mRNAs. Such regulation is important for maintaining proper cellular responses to external stress factors.
Pathways
HNRNPA0 is involved in the p38 MAPK signaling pathway where it influences the stability of mRNAs encoding inflammatory mediators. It also plays a part in the apoptotic pathway where it interacts with proteins such as TRAF2 and apoptosis as death domain-like protein (ADRP). Through these pathways HNRNPA0 contributes to cellular stress responses inflammation and programmed cell death linking it to essential cellular processes.
HNRNPA0 has been implicated in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) where protein aggregates may form due to dysregulation of HNRNPA0 activity. It is also associated with certain types of cancer such as leukemia where altered expression levels may impact mRNA stability and cell proliferation. Through these disease contexts HNRNPA0 interacts with proteins like TDP-43 in ALS and has connections to proto-oncogenes in cancer highlighting its potential role as a therapeutic target.
